Spyre Therapeutics, Inc. (SYRE)
| Market Cap | $8.91B+307.9% |
| Revenue (ttm) | n/a |
| Net Income | -$224.00M |
| EPS | -$2.49 |
| Shares Out | 94.97M |
| PE Ratio | n/a |
| Forward PE | -25.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,102,434 |
| Open | $98.70 |
| Previous Close | $99.37 |
| Day's Range | $92.95 - $100.03 |
| 52-Week Range | $23.01 - $110.64 |
| Beta | 3.23 |
| Analysts | Strong Buy |
| Price Target | $123.87(+32.04%) |
| Earnings Date | Nov 3, 2026 |
About SYRE
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating SYRE in the last 3 months, one vote each. Issuer-paid research is not counted.
$SYRE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SYRE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SYRE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SYRE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SYRE Revenue by Segment
| Stock-based compensation | $40.48M | 76.34% |
| Compensation | $12.55M | 23.66% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New SYRE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SYRE from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from SYRE’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst upgrades and price target increases dominate, offset modestly by one trim; earnings and corporate updates support bullish momentum.
Recent Insider Activity
Insider Score Trend Over Time
-33.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| LFSC | F/M Emerald Life Sciences Innovation ETF | 4.28% |
| QMOM | Alpha Architect U.S. Quantitative Momentum ETF | 2.57% |
| TDNA | T. Rowe Price Biotech ETF | 2.10% |
| XBI | State Street SPDR S&P Biotech ETF | 1.77% |
| FCMO.TO | Fidelity U.S. Momentum Index ETF | 1.47% |
| MMSC | First Trust Multi-Manager Small Cap Opportunities ETF | 1.24% |
| SGRW | Harbor Active Small Cap Growth ETF (SGRW) | 1.17% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.98% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.89% |
| MEDI | Harbor Health Care ETF (MEDI) | 0.78% |
| GSC | Goldman Sachs Small Cap Equity ETF | 0.75% |
| ESSC | Eventide Small Cap ETF | 0.62% |
Weight is the stock’s share of each fund’s holdings.
